Group 1 - The article reports on share buybacks conducted by various companies on December 22, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent [1] - Tencent Holdings repurchased 1.035 million shares for a total of 636 million yuan, representing 1.052% of its total share capital for the year [2] - Other notable companies involved in the buyback include Xiaomi Group (01810), which repurchased 3.75 million shares for 149 million yuan, and China COSCO Shipping Holdings (01919), which repurchased 4.15 million shares for approximately 56.6 million yuan [2] Group 2 - The total number of shares repurchased by various companies varies significantly, with some companies like Huohai Biotechnology (06826) and Juzhi Biotechnology (02367) showing higher percentages of their total share capital repurchased [3] - For instance, Huohai Biotechnology repurchased 17,000 shares, accounting for 6.429% of its total share capital, while Juzhi Biotechnology repurchased 400,000 shares, representing 0.373% of its total [3] - The data indicates a trend of companies engaging in share buybacks as a strategy to enhance shareholder value and potentially stabilize stock prices during uncertain market conditions [1][2]

Core Viewpoint - The company, Giant Bio (02367.HK), has been actively repurchasing its shares, indicating a potential confidence in its stock value and a strategy to enhance shareholder value through buybacks [1] Group 1: Share Buyback Details - On December 22, the company repurchased 400,000 shares at a price range of HKD 35.860 to HKD 36.340, totaling HKD 14.4297 million [1] - The stock closed at HKD 36.060 on the same day, reflecting a 1.63% increase, with a total trading volume of HKD 192 million [1] - Since December 9, the company has conducted buybacks for 10 consecutive days, accumulating a total of 4 million shares repurchased at a total cost of HKD 141 million [1] Group 2: Historical Buyback Data - The buyback details for the past days are as follows: - December 19: 40,000 shares at a maximum price of HKD 35.520 and a total cost of HKD 14.0536 million [1] - December 18: 40,000 shares at a maximum price of HKD 35.040 and a total cost of HKD 13.8830 million [1] - December 17: 40,000 shares at a maximum price of HKD 35.220 and a total cost of HKD 13.9713 million [1] - December 16: 40,000 shares at a maximum price of HKD 35.400 and a total cost of HKD 14.0261 million [1] - December 15: 40,000 shares at a maximum price of HKD 35.240 and a total cost of HKD 13.9173 million [1] - December 12: 40,000 shares at a maximum price of HKD 35.220 and a total cost of HKD 14.0364 million [1] - December 11: 40,000 shares at a maximum price of HKD 35.360 and a total cost of HKD 13.8876 million [1] - December 10: 40,000 shares at a maximum price of HKD 36.220 and a total cost of HKD 14.3824 million [1] - December 9: 40,000 shares at a maximum price of HKD 36.180 and a total cost of HKD 14.3764 million [1]

Company News - Vanke Enterprise (02202.HK) has extended the grace period for the principal and interest payment of its fourth tranche of medium-term notes (total principal of 2 billion yuan) to 30 trading days [1] - Cathay Pacific Airways (00293) reported a passenger count of 2.5304 million in November, representing a year-on-year increase of 26% [1] - Shandong High New Energy (01250.HK) announced that its subsidiary Wuxiang Beiqing Smart Energy has signed an EPC contract with China Railway 17th Bureau, with a total contract value of 405.5 million yuan [1] - China General Nuclear Power (01816) reported that the commissioning of Units 1 and 2 in Huizhou has been adjusted, with expected operational dates moved to the first half and second half of 2026, respectively [1] Strategic Partnerships - Lehua Entertainment (02306.HK) has signed a business cooperation framework agreement with Youku Information Technology and Youku for 2026 [2] - Xinbao Global Holdings (00723.HK) has entered into a cooperation agreement with Guangxi Fenglin (601996.SH) to jointly develop the EU wood board and related product market [2] - Dipo Technology (01384.HK) has established a strategic cooperation agreement with Muxi Co., aiming to deepen collaboration in enterprise-level large model AI applications across key industries such as manufacturing, commercial circulation, transportation, and healthcare [2] Product Development - He Yu-B (02256.HK) announced that its CSF-1R inhibitor Beijiemai® has received approval from China's NMPA [3] - Saint Noble Pharmaceuticals-B (02257.HK) has completed Phase I trials for its investigational drug STP707 and has formally submitted the clinical research report to the FDA [4] - Nanshan Aluminum International (02610.HK) has increased its annual production capacity for alumina to 4 million tons [5] Share Buybacks - Tencent Holdings (00700.HK) repurchased 1.035 million shares at a cost of 636 million HKD, with repurchase prices ranging from 610.5 to 620 HKD [8] - Xiaomi Group-W (01810.HK) spent approximately 149 million HKD to repurchase 3.75 million shares, with prices between 37.61 and 42.50 HKD [9] - Giant Bio (02367.HK) repurchased approximately 14.43 million HKD worth of 400,000 shares, with prices between 34.71 and 36.34 HKD [10]

Group 1 - The company, Giant Bio (02367.HK), announced a share buyback on December 22, spending HKD 14.43 million to repurchase 400,000 shares [1]

智通财经APP讯，巨子生物(02367)公布，2025年12月22日耗资约1442.97万港元回购40万股股份。 ...

巨子生物(02367)公布，2025年12月22日耗资约1442.97万港元回购40万股股份。 ...

公司名稱： 巨子生物控股有限公司 呈交日期： 2025年12月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) ...

Core Insights - Nordberg Medical and Giant Bio have signed a strategic cooperation agreement to advance the global development and commercialization of recombinant collagen in the medical aesthetics and biomedical fields [1][2] Group 1: Strategic Partnership - The agreement grants Nordberg Medical the rights to develop, produce, and commercialize Giant Bio's patented recombinant collagen outside of mainland China [1] - This collaboration aims to develop multiple tissue regeneration products for the medical aesthetics sector, leveraging the low immunogenicity and virus-free characteristics of Giant Bio's recombinant collagen [1] Group 2: Market Potential - The injection-based medical aesthetics market is projected to reach a market size of $10 billion by 2026, highlighting significant growth opportunities for the partnership [2] - The collaboration is expected to enhance Nordberg Medical's innovation capabilities in regenerative medicine by providing a richer product line [2] Group 3: Industry Impact - The partnership is seen as a milestone for both companies, with Giant Bio's technology being recognized as a "Chinese technology business card" in the international market [2] - The collaboration is anticipated to have a profound impact on the global medical aesthetics industry, promoting high-quality health solutions for consumers and practitioners [2]

Core Insights - Nordberg Medical and Giant Bio have signed a strategic cooperation agreement to jointly advance the global development and commercialization of recombinant collagen in the medical aesthetics and biomedical fields [1][2] Group 1: Strategic Cooperation - The agreement grants Nordberg Medical the rights to develop, produce, and commercialize Giant Bio's patented recombinant collagen in global markets outside mainland China [1] - This collaboration aims to enhance Nordberg Medical's position in the rapidly growing anti-aging regenerative solutions sector [1][2] Group 2: Market Potential - The injectable medical aesthetics market is projected to reach $10 billion by 2026, highlighting significant growth opportunities for Nordberg Medical [2] - The partnership is expected to diversify the product portfolio and strengthen innovation capabilities in regenerative medicine [2] Group 3: Company Background - Nordberg Medical is a Swedish biotechnology and medical device company focused on creating innovative biomedical solutions that connect nature and science [3] - The flagship brand, JULÄINE of Sweden™, features a new generation of collagen biostimulants that activate the body's natural collagen regeneration [3] - The company has received regulatory approvals for its products in 33 markets and is expanding its direct sales network across over 20 countries, with plans to enter North America, South America, and the Middle East [4]

Summary of Key Points Core Viewpoint - A total of 40 companies conducted share buybacks on December 19, 2025, with Tencent Holdings (00700) leading in both the number of shares repurchased and the total amount spent on buybacks. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 1.038 million shares for a total of 636 million yuan, with a year-to-date cumulative buyback of 95.679 million shares, representing 1.041% of its total share capital [2]. - Xiaomi Group-W (01810) repurchased 3.75 million shares for 152 million yuan, with a cumulative buyback of 127 million shares, accounting for 0.490% of its total share capital [2]. - China Merchants Industry Holdings (01919) repurchased 3.9655 million shares for 53.6689 million yuan, with a cumulative buyback of 105 million shares, representing 3.635% of its total share capital [2]. Group 2: Other Notable Buybacks - Kuaishou-W (01024) repurchased 755,000 shares for 49.9509 million yuan, with a cumulative buyback of 13.2687 million shares, accounting for 0.310% of its total share capital [2]. - China Feihe (06186) repurchased 8.529 million shares for 35.7702 million yuan, with a cumulative buyback of 251 million shares, representing 2.765% of its total share capital [2]. - Geely Automobile (00175) repurchased 907,000 shares for 15.2602 million yuan, with a cumulative buyback of 18.012 million shares, accounting for 0.179% of its total share capital [2]. Group 3: Additional Companies - Other companies that conducted buybacks include Mengniu Dairy (02319), which repurchased 200,000 shares for 3.0643 million yuan, and Beike-W (02423), which repurchased 560,400 shares for 3 million yuan [2]. - The buyback activities reflect a strategic move by these companies to enhance shareholder value and signal confidence in their business prospects [1][2].